Caprion Announces Expansion of Biomarker Discovery Collaboration with Vertex
The initial collaboration with Vertex was announced in March 2006. The expanded collaboration will continue to apply Caprion's CellCarta® proteomics biomarker technology across preclinical and clinical development activities being conducted by Vertex.
"We believe this expanded collaboration reflects the interest of biotechnology companies to integrate biomarker discovery efforts into major drug development programs," noted Dr. Daniel Chelsky, Executive Vice-President and Chief Scientific Officer at Caprion.
"Caprion is pleased with the progress made under the original collaboration with Vertex, and we look forward to further broadening the collaboration in the coming months."